It is a link for moving within the page.

  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2010
  5. Starting co-promotion of the anti-cancer agent “SPRYCEL® Tablet 20mg and SPRYCEL® Tablet 50mg” (dasatinib) in Japan

December 21, 2010

Bristol-Myers K.K.
Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals

Starting co-promotion of the anti-cancer agent
“SPRYCEL® Tablet 20mg and SPRYCEL® Tablet 50mg” (dasatinib)
in Japan

Tokyo, Japan -- Bristol-Myers K.K. (Headquarters: Shinjuku-ku, Tokyo; President and CEO: Emmanuel Blin) and Otsuka Pharmaceutical Co., Ltd. (Head Office: Chiyoda-ku, Tokyo; President: Taro Iwamoto) will start co-promotion activities on the sales of the anti-cancer agent "SPRYCEL Tablet 20mg and SPRYCEL Tablet 50mg" (dasatinib) in Japan on January 1st, 2011.


Information in this news release was current as of the original release date.

Latest Pharmaceutical Business related News Releases

Most Recent Releases